Jazz Pharmaceuticals plc
- JAZZ
- NASDAQ
- Biotechnology
- Sleep Disorder Drugs (Xywav)
- Epilepsy Drugs (Epidiolex)
$207.60
Today −1.25%Quote Oct 19, 2026, 02:05 PM UTC
−13.78%over the last month
Max drawdown −14.0%From 1-month high −13.8%3 months −13.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$13.48B
Quote Oct 19
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$292.80
+41.0% from here
Floor
$197.83
4.7% below price
Where the price sits
48 analysts
Analyst range, low to high
$229.00$337.00
- Price $207.60
- Resistance $208.12
- Consensus $292.80
The price is right under resistance. Analysts' average target sits about 41% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about JAZZPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $1.21B
- Xywav$471.2M39.0%
- Epidiolex/Epidyolex$292.1M24.2%
- Zepzelca$105.8M8.8%
- Rylaze/Enrylaze$99.5M8.2%
- Defitelio/Defibrotide$62.0M5.1%
- High Sodium AG Oxybate Product Royalty Revenue$42.2M3.5%
- Vyxeos$31.4M2.6%
- Xyrem$30.5M2.5%
- Ziihera$15.4M1.3%
- Other Royalty And Contract Revenues$10.0M0.8%
- Other / not reported$48.2M4.0%
Industry
Biotechnology
Employees
2,890
Founded
2003